Global death rates and levels of disability among newborns with pulmonary arterial hypertension (PAH) have declined since 1990, while…
Articles by Steve Bryson, PhD
Researchers used computer-based modeling to develop a measure, called pulmonary vascular compromise (PVC), which estimates the reduced function of the…
A new sequential strategy successfully treats people with severe chronic thromboembolic pulmonary hypertension (CTEPH), significantly reducing high blood pressure…
Winrevair (sotatercept-csrk), when added to standard of care, reduced clinical worsening events by 76% in adults recently diagnosed with…
Stem cell-derived conditioned medium, or the liquid that remains after cells are cultured, reduces the signs of pulmonary arterial…
Phaware, a global advocacy organization, is launching a special podcast series to raise awareness of pulmonary arterial hypertension…
People with pulmonary hypertension (PH) face significant obstacles when seeking timely care, with barriers arising at each stage from…
Tectonic Therapeutic plans to launch a Phase 2 clinical trial to test the impact of its therapy candidate TX45…
Having pulmonary hypertension (PH) increases the risk of death, both in the short and long term, for individuals undergoing…
People with pulmonary arterial hypertension (PAH) with at least one coexisting condition associated with cardiovascular disease had similar rates…
Following the first commercial sale of Yutrepia (treprostinil) inhalation powder to treat certain types of pulmonary hypertension, the…
Beyond Air has submitted a supplement application to the U.S. Food and Drug Administration (FDA) for its LungFit PH…